Jacob Sloane, MD, PhD
Basic profileJacob Sloane is a Neurology physician affiliated with Beth Israel Deaconess Medical Center. OpenAlex indexes 136 publications with 3,741 citations (h-index 28).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GenzymeProgram year20253 paymentsResearch$74,358
- NovartisProgram year20251 paymentResearch$593
- GENZYME CORPORATIONProgram year20252 payments$205
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
62.4%Benzodiazepine11.6%Clonazepam41%Lorazepam33%Diazepam15%Alprazolam12%Part D<11 patientsGabapentinoids9.5%Gabapentin89%Pregabalin11%Part D<11 patients+ 21 more classes in this area
Cancer & immunology
17.9%Other immunostimulants4.6%Copaxone78%Glatiramer Acetate22%Part D<11 patientsOther immunosuppressants4.3%Dimethyl Fumarate54%Tecfidera30%Vumerity16%Part D<11 patients+ 4 more classes in this area
Musculoskeletal
10.4%gamma-Aminobutyric Acid-ergic Agonist7.3%Baclofen100%Part D≥57 patientsCentral alpha-2 Adrenergic Agonist1.1%Tizanidine Hcl100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate
Multiple Sclerosis Journal
2023 - Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease
Multiple Sclerosis and Related Disorders
2022 - Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression
Brain Communications
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Matcheri Keshavan, MD
Beth Israel Deaconess Medical Center
Connie Tsao, MD
Beth Israel Deaconess Medical Center
Donald Cutlip, MD
Beth Israel Deaconess Medical Center
Robert Yeh, MD
Beth Israel Deaconess Medical Center
Bruce Miller, MD
University of California, San Francisco (UCSF)
David Knopman, MD
Mayo Clinic Rochester
Brett Kissela, MD
Medical College of Wisconsin
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”